DanCann Pharma Income Statement

Financials in millions DKK. Fiscal year is January - December.

Millions DKK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019
Revenue	7.37	7.15	7.19	2.31	-	Upgrade
Revenue Growth (YoY)	3.06%	-0.50%	211.89%	-	-	Upgrade
Cost of Revenue	7.77	10.88	12.9	8.8	2.84	Upgrade
Gross Profit	-0.4	-3.72	-5.71	-6.49	-2.84	Upgrade
Selling, General & Admin	4.77	9.45	8.52	7.12	2.94	Upgrade
Other Operating Expenses	-0.04	-0.28	-0.04	-	-	Upgrade
Operating Expenses	6.76	56.39	10.71	8.01	3.04	Upgrade
Operating Income	-7.15	-60.12	-16.42	-14.51	-5.87	Upgrade
Interest Expense	-1.33	-2.33	-3.02	-1.26	-0.14	Upgrade
Interest & Investment Income	0.14	0.2	1.19	0.58	0.02	Upgrade
Pretax Income	-8.35	-62.24	-18.25	-15.19	-5.99	Upgrade
Income Tax Expense	-	0.02	-2.19	-3.44	-1.73	Upgrade
Net Income	-8.35	-62.26	-16.06	-11.75	-4.26	Upgrade
Net Income to Common	-8.35	-62.26	-16.06	-11.75	-4.26	Upgrade
Shares Outstanding (Basic)	4	0	0	0	-	Upgrade
Shares Outstanding (Diluted)	4	0	0	0	-	Upgrade
Shares Change (YoY)	2718.02%	117.84%	187.73%	-	-	Upgrade
EPS (Basic)	-2.09	-439.60	-247.08	-520.00	-	Upgrade
EPS (Diluted)	-2.09	-439.60	-247.08	-520.00	-	Upgrade
Free Cash Flow	-5.24	-12.04	-12.74	-18.36	-11.68	Upgrade
Free Cash Flow Per Share	-1.31	-85.03	-195.89	-812.31	-	Upgrade
Gross Margin	-5.37%	-52.03%	-79.44%	-281.73%	-	Upgrade
Operating Margin	-97.03%	-840.42%	-228.38%	-629.41%	-	Upgrade
Profit Margin	-113.21%	-870.40%	-223.45%	-509.76%	-	Upgrade
Free Cash Flow Margin	-71.03%	-168.35%	-177.16%	-796.31%	-	Upgrade
EBITDA	-5.13	-56.74	-14.19	-13.62	-5.78	Upgrade
EBITDA Margin	-69.55%	-	-197.34%	-	-	Upgrade
D&A For EBITDA	2.03	3.38	2.23	0.89	0.09	Upgrade
EBIT	-7.15	-60.12	-16.42	-14.51	-5.87	Upgrade
EBIT Margin	-97.03%	-	-228.38%	-	-	Upgrade

Updated Feb 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.